Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus low dose IL-2 in Systemic Lupus Erythematosus
NCT05262686Phase 3Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldesleukin in systemic lupus erythematosus (SLE), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05262686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262686.